Inovio Pharmaceuticals Advances DNA Medicine Pipeline

Inovio Pharmaceuticals ( (INO) ) has released its Q1 earnings. Here is a breakdown of the information Inovio Pharmaceuticals presented to its investors.

Inovio Pharmaceuticals is a biotechnology company specializing in the development and commercialization of DNA medicines aimed at treating and protecting against HPV-related diseases, cancer, and infectious diseases. The company is recognized for its innovative DNA plasmid technology and proprietary CELLECTRA delivery devices.

Inovio Pharmaceuticals recently released its financial results for the first quarter of 2025, highlighting significant advancements in its product pipeline. The company is on track to begin the rolling submission of its Biologics License Application (BLA) for INO-3107, a potential treatment for recurrent respiratory papillomatosis (RRP), by mid-2025. Additionally, promising interim results from a Phase 1 trial of its DNA-encoded monoclonal antibodies (DMAbs) technology were announced.

Key financial metrics from the first quarter of 2025 show a decrease in research and development expenses to $16.1 million, down from $20.9 million in the same period of 2024, and a reduction in general and administrative expenses to $9.0 million from $10.6 million. The company’s net loss also decreased to $19.7 million, or $0.51 per share, compared to a net loss of $30.5 million, or $1.31 per share, in the previous year. Inovio’s cash, cash equivalents, and short-term investments stood at $68.4 million as of March 31, 2025.

Inovio is optimistic about the potential of INO-3107, which has been granted breakthrough therapy designation by the FDA. The company plans to request priority review for its BLA, potentially leading to an FDA approval decision by mid-2026. Inovio is also encouraged by the durability and safety profile of its DMAbs technology, which could offer a novel approach to antibody production.

Looking forward, Inovio Pharmaceuticals remains focused on advancing its pipeline of DNA medicines and is confident in its ability to bring innovative treatments to market. The company projects its current cash resources will support operations into the first quarter of 2026, as it continues to explore strategic opportunities to enhance its financial position.